araag2/HINT huggingface dataset:
Clinical trial NCT01392105 (phase 2/phase 3, status: completed)
Conditions: acute myocardial infarction
ICD codes: I21.9, I23.8, I23.0, I24.0, I23.1, I23.2, I23.4
Drugs: mesenchymal stem cell, control group
SMILES: [Na+].[Cl-]
Eligibility criteria:

        Inclusion Criteria:

          -  aged 18-70 years

          -  ischemic chest pain for >30 min

          -  admitted to hospital <24 h after the onset of chest pain

          -  electrocardiography showed ST segment elevation >1 mm in two consecutive leads in the
             limb leads or >2 mm in the precordial leads

          -  they could be enrolled in the study <72 h after successful revascularization

        Exclusion Criteria:

          -  cardiogenic shock (defined as systolic blood pressure <90 mmHg requiring intravenous
             pressors or intra-aortic balloon counterpulsation)

          -  life-threatening arrhythmia

          -  impossible conditions for cardiac catheterization

          -  advanced renal or hepatic dysfunction

          -  history of previous coronary artery bypass graft

          -  history of hematologic disease

          -  history of malignancy

          -  major bleeding requiring blood transfusion

          -  stroke or transient ischemic attack in the previous 6 months

          -  structural abnormalities of the central nervous system (brain tumor, aneurysm, history
             of surgery)

          -  traumatic injury after myocardial infarction

          -  use of corticosteroids or antibiotics during the previous month

          -  major surgical procedure in the previous 3 months

          -  cardiopulmonary resuscitation for >10 min within the previous 2 weeks

          -  positive skin test for penicillin

          -  positive result for viral markers (human immunodeficiency virus (HIV), hepatitis B
             virus (HBV), hepatitis C virus (HCV) and Venereal Disease Research Laboratory (VDRL)
             test)

          -  pregnancy, possible candidate for pregnancy or breastfeeding females

          -  drug abusers

          -  inappropriate patients to participate in the study according to the chief investigator
Clinical trial NCT00313885 (phase 2, status: completed)
Conditions: fibromyalgia, sleep, chronic pain
ICD codes: M79.7, Z72.820, G47.21, G47.22, G47.23, F51.12, G47.30, G47.39, G89.29, G89.4, R39.82, G89.22, G89.28, G89.21, G89.3
Drugs: eplivanserin (sr46349), placebo
SMILES: CN(C)CCO\N=C(\C=C\C1=CC=C(O)C=C1)/C1=CC=CC=C1F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Each patient must fulfill the diagnosis criteria of fibromyalgia according to the
             American College of Rheumatology

          -  Based on patient's information:

          -  The patient must complain of unrefreshing sleep for at least 3 nights per week over
             the past month.

          -  The patient spends at least 6.5 hours and not more than 9 hours, in bed, each night
             over the past 2 weeks.

          -  Female patients of childbearing potential must have a confirmed negative pregnancy
             test at the end of the screening period and use an acceptable method of birth control
             throughout the study

          -  Written, signed and dated informed consent must be obtained from each patient

          -  Willing to abstain from taking any medication or treatment prohibited as per the
             protocol

        Exclusion Criteria:

          -  Females who are lactating or pregnant

          -  Night shift workers, and individuals who nap 3 or more times per week over the
             preceding month (nap: intentionally sleeping for more than 20 minutes during the day).

          -  Consumption of beverage with caffeine (i.e. tea, coffee, or cola) comprising more than
             2 cups or glasses per day

          -  Past or Current medical history of any significant, severe, or unstable acute or
             chronically progressive medical or surgical disorder which may affect patient safety
Clinical trial NCT01203631 (phase 2, status: completed)
Conditions: inflammation, crohn's disease
ICD codes: H01.9, H30.93, H05.00, H30.003, H30.013, H30.033, H30.103, K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: nnc 0142-0000-0002, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with CD for at least 3 months

          -  Subjects not treated before, or subjects who have either not responded to treatment,
             or responded and then lost the response during continued administration of a
             therapeutic compound

        Exclusion Criteria:

          -  Any of the following: Symptomatic bowel obstruction, short bowel syndrome, ileostomy
             or colostomy, surgical bowel resection within 6 months prior to randomisation or
             clinically relevant un-drained abscess

          -  History of dysplasia or malignancy in the colon

          -  Any ongoing chronic or active infectious disease or microbial infection requiring
             systemic oral or intravenous treatment against infection within 1 month prior to
             randomisation

          -  Body mass index (BMI) higher or equal to 38.0 kg/m^2
Clinical trial NCT01329978 (phase 2, status: completed)
Conditions: hepatitis c, chronic
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: sofosbuvir, rbv, peg
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females with Chronic Hepatitis C (HCV) Genotype 1,4,5,6, or indeterminate

          -  Naive to previous HCV treatment

        Exclusion Criteria:

          -  Positive for HBsAg, anti-HBc IgM Ab, or anti-HIV Ab

          -  History of any other clinically significant chronic liver disease
Clinical trial NCT00585533 (phase 2, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: erlotinib (tarceva)
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Eligibility criteria:

        Inclusion Criteria:

          -  Performance status 0-1.

          -  Weight Loss < 10% in preceding 3 months

          -  Age 18 years and older.

          -  Adjuvant chemotherapy allowed if > 6 months from protocol entry

          -  Adequate Organ Function

          -  Liver enzymes < 2X normal, bilirubin = normal

          -  Oxygen saturation> 89% on room air unless chronically oxygen dependent (not cancer
             related)

          -  Creatinine <2.0 mg

        Exclusion Criteria:

          -  Not pregnant or lactating.

          -  No Clinical Brain Metastases

          -  No prior chemotherapy for systemic disease

          -  Imminent need for chemotherapy for impending organ dysfunction is not allowed
Clinical trial NCT01286077 (phase 2, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: bortezomib
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Adult Multiple Myeloma patients in partial response or better after high dose
             chemotherapy and autologous stem cell transplantation

          -  Patient fulfills defined laboratory requirements within 14 days before enrolment

          -  If female, is either postmenopausal for more than 24 consecutive months or surgically
             sterilized or willing to use an acceptable method of birth control for defined period

          -  If male, agree to use an acceptable barrier method of contraception and to not donate
             sperm up to 3 months following treatment

        Exclusion Criteria:

          -  Patient received another antimyeloma or experimental therapy following autologous stem
             cell transplantation

          -  Patient has a peripheral neuropathy or neuropathic pain of grade 2 or greater
             intensity as defined by the NCI common terminology criteria of adverse event (NCI
             CTCAE) version 3.0

          -  Patient has an uncontrolled or severe cardiovascular disease within 6 months of
             enrolment

          -  Patient has any conditions that would compromise his/her well-being or the completion
             of the study requirements
Clinical trial NCT01100151 (phase 2, status: completed)
Conditions: opioid-induced constipation
ICD codes: F11.14, F11.181, F11.182, F11.188, F11.19, F11.24, F11.281
Drugs: rdc-1036 (alks 37), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  18 to 70 years of age

          -  Body mass index (BMI) of 19 to 35 kg/m2 at screening

          -  Receiving prescribed opioid medication for the management of chronic, non-cancer, pain

          -  Diagnosis of opioid-induced constipation (OIC)

          -  Willingness to stop all laxatives and other bowel regimens from the first study visit
             following screening until the end of the study. The use of constipation rescue
             medication will be allowed during the study.

        Exclusion Criteria:

          -  Pregnancy and/or currently breastfeeding

          -  Clinically significant medical condition or illness (other than the condition for
             which the pain medication is being prescribed)

          -  Receiving treatment with opioid therapy for cancer-related pain, abdominal pain,
             scleroderma, and/or for the management of drug addiction

          -  Any gastrointestinal (GI) or pelvic disorder known to affect bowel transit, produce a
             GI obstruction, or contribute to bowel dysfunction other than opioid-induced
             constipation (eg, diverticulitis, other intestinal strictures, bezoars)

          -  Use of medical devices such as pacemakers, infusion pumps, or insulin pumps

          -  Use of naloxone, Subutex or Suboxone, Revia, Relistor, or Entereg starting 15 days
             before the first study visit following screening until the end of the study

          -  Participation in a clinical trial of a pharmacological agent within 30 days before
             screening
Clinical trial NCT00120783 (phase 2, status: terminated)
Conditions: hiv infections
ICD codes: Z21
Drugs: indinavir, lamivudine, ritonavir
SMILES: CC(C)(C)NC(=O)[C@@H]1CN(CC2=CN=CC=C2)CCN1C[C@@H](O)C[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]1[C@H](O)CC2=CC=CC=C12, CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  HIV-1 infection confirmed by Western Blot

          -  Karnofsky score over or equal to 70

          -  CD4 over or equal to 200/mm3

          -  Plasma viral RNA over or equal to 10 000 copies/ml and below 100 000 copies/ml.

          -  Stability of plasma viral load and CD4-during the last 3 months

          -  failure of two antiretroviral regimens with 2 PI and one NNRTI

          -  New efficacy drug on genotype not available

          -  Treatment on hand with 3 antiretroviral drugs with one PI since 3 months.

          -  Written inform consent

          -  Pregnancy

        Exclusion Criteria:

          -  Hemoglobin below 8g/dL

          -  Neutrophils below 750/mm3

          -  ASAT, ALAT over 5N

          -  Hepatic insufficiency (prothrombin below 50%)

          -  Acute opportunistic infection

          -  Immunotherapy

          -  Treatment with active antiretroviral regimen

          -  Treatment with enzyme inductor
Clinical trial NCT01283724 (phase 2, status: completed)
Conditions: endometriosis
ICD codes: N80.8, N80.9, N80.0, N80.1, N80.5, N80.2, N80.3
Drugs: dienogest (visanne, bay86-5258)
SMILES: [H][C@@]12CC[C@@](O)(CC#N)[C@@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@]21[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Female adolescents after menarche (12 - less than 18 years of age) at screening. For
             Finland: Adolescents aged 12 - 14 years old who present with clinical features of
             endometriosis will only be enrolled into the study if their diagnosis of endometriosis
             has been confirmed by laparoscopy.

          -  Dysmenorrhea of at least moderate intensity, with or without chronic pelvic pain, for
             at least 2 cycles in the previous 4 months and one of the following conditions:

               -  Clinically suspected endometriosis based on the presence of pelvic pain
                  incompletely relieved by non steroidal anti-inflammatory drugs and/or oral
                  contraceptives

               -  Any abdominal pain associated with ultrasound findings suggestive of
                  endometriosis (abdominal, vaginal or rectal; only after additional specific
                  consent and assent)

               -  Failure of surgical treatment for endometriosis (with cyclic or chronic pelvic
                  pain of at least 4 months duration postsurgery)

               -  Threshold for endometriosis-associated pelvic pain (EAPP) score: at least 30 on a
                  100 units visual analog scale retrospectively evaluated at screening for the last
                  4 weeks

        Exclusion Criteria:

          -  Absence of endometriosis at laparoscopy

          -  Previous application of hormonal agents including oral contraceptives within 2 months,
             progestins, danazol within 3 months, and Gonadotropin Releasing Hormone (GnRH)
             agonists within 6 months prior to start of treatment

          -  Chronic pelvic pain that might be related to genitourinary disease or to chronic or
             recurrent gastrointestinal disease, including irritable bowel syndrome (defined as a
             disease characterized by pain relieved by defecation and irregular defecation patterns
             lasting at least 3 months)

          -  Clinically established need for primary surgical treatment of endometriosis
Clinical trial NCT01150890 (phase 2, status: terminated)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: amg 827 350 mg, amg 827 210 mg, amg 827 700 mg, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    per recommendation from drt
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with ileal, ileo-colonic, or colonic Crohn's disease for a minimum of 6
             months prior to initiating Study Product

          -  Moderately to severely active Crohn's disease, as defined by a CDAI score >250 and
             <450 at baseline

          -  Evidence of active inflammation

        Exclusion Criteria:

          -  Short bowel syndrome

          -  Stricture with obstructive symptoms within 3 months

          -  Bowel surgery within 3 months

          -  Ileostomy and/or colostomy

          -  Any gastric or intestinal pouch

          -  Ulcerative colitis

          -  Evidence of an infected abscess

          -  Bowel perforation or evidence of noninflammatory obstruction during the 6 months Stool
             positive for C. Difficile toxin at screening

          -  Presence of active infection requiring treatment

          -  Serious infection within 8 weeks

          -  Significant concurrent medical conditions

          -  Pregnant or breast feeding

          -  Significant Laboratory abnormalities

          -  Any anti-TNF agent within 2 months

          -  Steroid enemas within 2 weeks

          -  Tysabri (natalizumab) within 1 year

          -  Biologic agents (eg, ustekinumab), experimental procedures, or live vaccines within 3
             months

          -  Cyclosporine, mycophenolate mofetil, sirolimus (rapamycin),thalidomide or tacrolimus
             within 2 months
Clinical trial NCT01471379 (phase 2, status: terminated)
Conditions: irritable bowel syndrome
ICD codes: K58.2, K58.8, K58.0, K58.1, K58.9
Drugs: milnacipran, milnacipran, milnacipran, placebo
SMILES: CCN(CC)C(=O)C1(CC1CN)C1=CC=CC=C1, CCN(CC)C(=O)C1(CC1CN)C1=CC=CC=C1, CCN(CC)C(=O)C1(CC1CN)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    due to recruitment difficulties the study is terminated.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Meet Rome III criteria for IBS and have no red flags.

          -  Must have had a colonoscopy within the previous 5 years to exclude inflammatory or
             other bowel disease

          -  Be fluent and literate in English

          -  Must either be of non-childbearing potential or agree to utilize approved birth
             control for the duration of the study

        Exclusion Criteria:

          -  Diagnosis or treatment of any clinically symptomatic biochemical or structural
             abnormality of the GI tract within 6 months prior to screening, or active disease
             within 6 months prior to screening.

          -  Any other diagnosis to explain the abdominal pain,

          -  Clinical evidence of significant cardiovascular, respiratory, renal, hepatic,
             gastrointestinal, hematologic, neurologic, psychiatric or any disease that may
             interfere with the subject successfully completing the trial

          -  Hepatic dysfunction (ALT [SGPT] or AST [SGOT] >3 times the upper limit of normal) or
             renal impairment (serum creatinine > 2mg/dL)

          -  Has disease affecting electrolytes balance, such as SIADH with serum Sodium less than
             130mmol/L

          -  Any evidence of or treatment of malignancy (other than localized basal cell, squamous
             cell skin cancer or cancer in situ that has been resected) within the previous year

          -  Any surgery on the stomach, small intestine or colon, excluding appendectomy

          -  A major psychiatric disorder (DSM-III-R or DSM-IV) including major depression or other
             psychoses that has required hospitalization in the last 1 year.

          -  History of attempted suicide or uncontrolled bipolar disorder.

          -  Currently using antidepressants for psychiatric conditions like major depression. Use
             of TCA or SSRI class antidepressant acceptable if being used specifically for
             treatment of bowel symptoms and patient is willing to taper off the medication

          -  Previous use of Milnacipran or other SNRI antidepressant (duloxetine, venlafaxine,
             desvenlafaxine)

          -  A diagnosis of seizure disorder

          -  A diagnosis of glaucoma

          -  Currently taking heparin or warfarin
Clinical trial NCT00737373 (phase 2, status: completed)
Conditions: gastric cancer, adenocarcinoma of the esophagogastric junction
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: docetaxel, 5-fluorouracil, oxaliplatin, folinic acid
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, FC1=CNC(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1
Eligibility criteria:

        Inclusion Criteria:

          -  metastatic or locally advanced gastric cancer or adenocarcinoma of the esophagogastric
             junction

          -  no prior chemotherapy in metastatic state

          -  adequate blood and biochemistry parameters

        Exclusion Criteria:

          -  hypersensitivity for 5-FU, Leucovorin, Oxaliplatin or Docetaxel

          -  KHK, cardiomyopathy or cardiac insufficiency

          -  malignancy <5 years ago

          -  brain metastases

          -  severe internal disease or inadequate blood and biochemistry parameters
Clinical trial NCT01438424 (phase 2, status: completed)
Conditions: hepatitis b virus, hbv
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: entecavir, lamivudine
SMILES: CCOC(=O)C1=CC=C(N)C=C1, CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
Eligibility criteria:

        Key inclusion criteria:

          -  Age of 16 years and older

          -  Receipt of entecavir or lamivudine in a previous entecavir study.

        Participants who were, based on their response to entecavir:

          -  Virologic nonresponders at Week 48

          -  Partial virologic responders who became nonresponders during the second year of
             treatment

          -  Partial virologic responders at Week 96

          -  Complete responders who relapsed during postdosing follow-up

               -  Decompensated liver disease in AI463-048 that met 1 or more of the following
                  criteria:

          -  Nonresponse to adefovir after at least 24 weeks of treatment

          -  Partial response to adefovir after 96 weeks of treatment

          -  Complete response to adefovir after relapsing during postdosing follow-up

          -  Demonstrated intolerance to adefovir

               -  Except for those participants enrolled from AI463-048, compensated liver disease.

        Key exclusion criteria:

          -  HIV coinfection

          -  Receiving nephrotoxic or hepatotoxic agents

          -  Ongoing opportunistic infections

          -  Hemoglobin level <11.0 g/dL except for those enrolled from AI463-048

          -  Platelet count <70,000 mm^3 except for those enrolled from AI463-048

          -  Absolute granulocyte count <1,500 cells/mm^3

          -  Recent history of pancreatitis (within 24 weeks prior to first dose of therapy)

          -  Current evidence of ascites requiring paracentesis, hepatic encephalopathy, or
             variceal bleeding, except for those enrolled from AI463-048

          -  Known history of allergy to nucleoside analogues.
Clinical trial NCT01356914 (phase 2, status: completed)
Conditions: atrial fibrillation
ICD codes: I48.0, I48.21, I48.91, I48.11, I48.19, I48.20
Drugs: bms-914392, bms-914392, bms-914392, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Paroxysmal atrial fibrillation (AF)

          -  Programmable dual chamber pacemaker with appropriate arrhythmia diagnostics.

          -  1-50% AF burden on pacemaker interrogation at screening.

          -  Women of childbearing potential (WOCBP) and men must be using an acceptable method of
             contraception to avoid pregnancy.

        Exclusion Criteria:

          -  Persistent or permanent AF.

          -  AF Burden <1% or > 50%.

          -  Current or history of neurological diseases and mental disorders.

          -  Ejection Fraction < 45%.

          -  Severe mitral or aortic valve dysfunction.

          -  TIA (Transient Ischemic Attack) within last 12 months.

          -  Acute coronary syndrome in the last 2 months.

          -  Previous AF ablation.

          -  Cardioversion in last 3 months.

          -  Current kidney or liver disease, or current cancer.

          -  History of neurological and mental disorders.

          -  Major surgery within 4 weeks of first dose (cardiac surgery within 4 months).

          -  Screening lab test results outside of allowed limits per protocol.

          -  QTcF > 450 msec.